Generate Life Sciences

generatelifesciences.com

Generate_Life_Sciences
Generate is a first-of-its-kind organization focused on helping grow and protect healthy families through reproductive, newborn stem cell, genetic screening, medical device and healthcare technology services. Generate serves families from preconception to post-birth throughout the significant and highly personalized journey of building a family and protecting their children’s health. Built upon the pillars of innovation, access, and connection, Generate has already helped grow and protect nearly 1 million families around the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

news image

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

Medical

BAKAR LABS AND THE CYSTIC FIBROSIS FOUNDATION SUPPORT ENTREPRENEURS TO DEVELOP NEW GENETIC THERAPIES FOR CF

Bakar Labs | April 19, 2022

news image

Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis. The CF Foundation is sponsoring a "Golden Ticket" competition at the new incubator and is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open M...

Read More

Industry Outlook

EXPANDING DIAGNOSTICS BUSINESS: SCHOTT SIGNS AGREEMENT TO ACQUIRE APPLIED MICROARRAYS INC.

Applied Microarrays Inc. | September 30, 2021

news image

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through th...

Read More

Industrial Impact

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

news image

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More
news image

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More
news image

Medical

BAKAR LABS AND THE CYSTIC FIBROSIS FOUNDATION SUPPORT ENTREPRENEURS TO DEVELOP NEW GENETIC THERAPIES FOR CF

Bakar Labs | April 19, 2022

Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis. The CF Foundation is sponsoring a "Golden Ticket" competition at the new incubator and is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open M...

Read More
news image

Industry Outlook

EXPANDING DIAGNOSTICS BUSINESS: SCHOTT SIGNS AGREEMENT TO ACQUIRE APPLIED MICROARRAYS INC.

Applied Microarrays Inc. | September 30, 2021

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through th...

Read More
news image

Industrial Impact

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us